March 14, 2012 09:00 AM Eastern Daylight Time

Mountain View Pharmaceuticals Announces Receipt of a U.S. Patent on Next-Generation PEGylation Technology (PharmaPEG)

Confirmatory Results Published in *Bioconjugate Chemistry*

MENLO PARK, Calif. – (BUSINESS WIRE) – Mountain View Pharmaceuticals, Inc. ("MVP") announced today its receipt of U.S. Patent No. 8,129,330 B2 titled "*Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof.*"

MVP also announced the publication of a peer-reviewed scientific article, titled "*Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates*" in the American Chemical Society journal, *Bioconjugate Chemistry.*

"MVP's PharmaPEG technology is the product of more than a decade of research and represents a major advance directed toward the multi-billion-dollar market for PEGylated proteins"

"The U.S. patent that was issued to MVP on March 6th has been granted more than five-and-one-half years of patent term adjustment, in recognition of the long delay between the filing of the application in 2002 and issuance of the patent. As a result, this patent is not scheduled to expire before mid-2028," stated Dr. Eldora Ellison, MVP's lead patent attorney at Sterne Kessler Goldstein & Fox, in Washington, D.C.

The new publication supports MVP's development of PharmaPEG conjugates and the patent protects the relevant intellectual property. PharmaPEG® is MVP's registered trademark for the most advanced generation of poly(ethylene glycol) ("PEG"). PharmaPEG forms less antigenic and less immunogenic conjugates than methoxyPEG ("mPEG"), which has been used in all existing PEGylated drugs. For a wide variety of proteins, including enzymes, serum proteins and cytokines, the reductions in immune responses to PharmaPEG conjugates, compared with mPEG conjugates of the same proteins, have ranged from 3-fold to >1,000-fold, as reported in *Bioconjugate Chemistry*. The decreased immunoreactivity results from replacement of the methoxy group of mPEG by a hydroxy group at the end of the polymer that is not attached to the protein.

Patents disclosing and claiming PharmaPEG conjugates have been granted to MVP previously in 18 other countries. MVP's recently issued U.S. patent, which includes 94 claims covering PharmaPEG conjugates of numerous classes of proteins, glycoproteins and peptides, will be a key component of the Company's business development and licensing activities.

"MVP's PharmaPEG technology is the product of more than a decade of research and represents a major advance directed toward the multi-billion-dollar market for PEGylated proteins," said Dr. Merry R. Sherman, CEO and President of MVP. "MVP's publication illustrating the advantages of PharmaPEG-protein conjugates, compared with conventional mPEG-protein conjugates, is expected to reach a wide audience of academic scientists, immunologists and pharmaceutical professionals."

About Mountain View Pharmaceuticals, Inc. (MVP)

MVP is a privately-held California corporation with expertise in the application of advanced polymer-coupling technology to make protein-based drugs safer and longer acting. To date, MVP has been granted 168 patents in 48 countries and regions. Of these patents, 105 are co-assigned to Duke University and are licensed to Savient Pharmaceuticals, Inc. for the right to make, use, offer for sale and sell pegloticase. This drug is a selectively PEGylated enzyme (uricase) that degrades uric acid and has been shown to be safe and effective for the treatment of adults with refractory chronic gout, who are unresponsive or allergic to other available treatments. On September 14, 2010, the U.S. FDA approved its sale by Savient under the trade name KRYSTEXXA. Additional information about MVP and about KRYSTEXXA is available at www.mvpharm.com and at www.krystexxa.com, respectively.

Contacts

Mountain View Pharmaceuticals, Inc.
Mark G. P. Saifer, Ph.D., 650-365-5515 x228
Vice President, Scientific Director
saifer@mvpharm.com